View Older Stories View More Recent Stories
-
Moderna to present cancer therapy data at ESMO Congress in October
-
Moderna Announces Data to be Presented at ESMO Congress 2025
-
Moderna receives positive EMA Committee opinion for COVID-19 mRNA Vaccine targeting the SARS-CoV-2 Variant LP.8.1
-
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
-
U.S. large biotech stocks Q2 earnings preview
-
Moderna (MRNA) cancels plans to build Japan plant
-
Brookline on Moderna (MRNA): 'We estimate COVID-19 vaccines could have 2025 global sales of $2.4 billion'
-
Moderna (MRNA) Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease
-
Moderna (MRNA) call put ratio 8.8 calls to 1 put with a focus on short duration July 11 weekly calls as share price up 11.5%
-
William Blair Reiterates Market Perform Rating on Moderna (MRNA) 'Competition in the space and waning vaccine sentiment are negatively impacting the base business'
-
Moderna (MRNA) Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
-
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
-
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
-
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
-
Kennedy Removing All Members Of CDC Panel Advising On Vaccines
-
FDA grants limited approval to Moderna's (MRNA) new mRNA COVID vaccine
-
Moderna (MRNA) introduces mNEXSPIKE, New COVID-19 Vaccine
-
Moderna (MRNA) call put ratio 1.3 calls to 1 put amid headlines
-
FDA Approves Moderna's (MRNA) Next-Gen COVID-19 Vaccine; Piper Sandler Reiterates OW
-
Moderna gains as FDA nod for next-gen COVID-19 vaccine
-
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
-
Moderna (MRNA) announces positive interim data from phase 1/2 study on flu vaccine
-
Moderna Announces Update on Investigational Pandemic Influenza Program
-
Moderna to Present at Upcoming Conferences in June 2025
-
Biotech stocks Q1 earnings review
-
Moderna (MRNA) files FDA application for Spikevax formula
-
Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
-
Kennedy Jr.'s 'MAHA' Report Expected to Criticize Chemicals in Food, Lobbyists and Vaccines, Sources Say -- WSJ
-
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA), PT $198
-
Moderna (MRNA) has voluntarily withdrawn the pending BLA for mRNA-1083
-
Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19
-
FDA Mandates Trials For Covid Boosters For Healthy Kids, Adults - NEJM
-
HHS plans to stop recommending Covid shots for children and pregnant women - WSJ
-
RFK Jr.'s HHS to Stop Recommending Routine Covid Shots for Kids, Pregnant Women -- WSJ
-
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
-
Trump: Dr. Casey Means Nominated For Surgeon General
-
Moderna (MRNA) call put ratio 1 call to 1.2 puts amid wide price movement
-
Moderna (MRNA) sees mid-day weakness
-
Berenberg Reiterates Hold Rating on Moderna (MRNA)
-
Moderna (MRNA) Tops Q1 EPS by 66c; offers guidance
-
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
-
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
-
Pharma stocks slide after Trump signals tariffs on sector
-
Moderna (MRNA) to Showcase Extensive Infectious Disease Research
-
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
-
Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
-
Brookline on Moderna (MRNA): 'Australia Authorizes RSV Vaccine,mRNA-1345 for Adults 60 Years and Older; Supports Our Outlook'
-
Truist: 'Expect Some Pressure On Dr. Marks' Resignation'
-
Moderna (MRNA) Falls 12% on Concerns About Vaccine Regulations
-
Moderna (MRNA) Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
